New testing, drugs may aid Alzheimer’s treatment
Trending
LANSING - Michigan ranks eighth in the country for Alzheimer's disease deaths, according to Ana Daugherty, the associate director of the Michigan Alzheimer's Disease Research Center and director of the Institute of Gerontology at Wayne State University.
Researchers like Daugherty are streamlining the process of Alzheimer's diagnosis as two FDA-approved drugs are in use to slow disease progression for those with early symptoms.
Lecanemab and donanemab are IV infusions that have shown the ability to slow declines in thinking and functioning for those with early Alzheimer's disease, according to the center. They were approved in 2023 and 2024 and are marketed under the names Leqembi and Kisunla, respectively.
The center combines professionals from the University of Michigan, Michigan State University and Wayne State University to conduct Alzheimer's and dementia research.
It's developing MRI tools to better screen candidates for Alzheimer's treatment and to monitor possible side effects, according to Daugherty.
Paula Cunningham, the state director of AARP Michigan, said she has spent years looking at ways to spot early signs of dementia and Alzheimer's, as well as promoting ways to delay the diseases' onset on her weekly "Real Possibilities" TV show.
"We used to say if you go in the basement and you forget what you went down there for, that's one thing. But if you go into the basement and you don't know where you are, that's something else," Cunningham said.
Cunningham said she recently learned about the drugs that can slow the progression of Alzheimer's and dementia, and it "almost made me cry."
Cunningham said she learned about the Alzheimer's treatments from the CEO and founder of BAMF Health, Anthony Chang.
The company based in Grand Rapids is the only site in the state capable of performing a brain MRI and an amyloid PET scan in a single visit to evaluate a patient's stage in dementia progression, according to BAMF Health.
These scans measure amyloid plaque accumulation in the brain, a key metric to diagnosing Alzheimer's disease and monitoring progression, according to the company.
Daugherty said developments in diagnostic technology like BAMF Health's PET/MR scanner are "a brand new frontier" for determining eligibility for Alzheimer's treatment.
"There's never been that kind of hope [before] about dementia," Cunningham said.
Daugherty said that by understanding biomarkers before symptoms have started, people can make more informed decisions about their care and living with Alzheimer's.
"I lost my grandmother to dementia, and something she taught me that I didn't learn from any of my research is that although they might forget who we are, they don't forget the feeling of being loved or of loving," Daugherty said.
"That's what really motivates me in this work, and that's why at the Institute of Gerontology, we don't just study problems. We put research into action so we can serve our Michigan communities."
About Kiera Kemppainen
Kiera is a junior majoring in political science and journalism with a concentration in writing, reporting, and editing. Her journalistic interests include government and community-focused news.